Essai clinique
Récupéré
Publication
clinicaltrials.gov
Seaside Therapeutics, Inc.
(2011).
A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome.
ClinicalTrials.gov.
Seaside Therapeutics, Inc..
- Date de publication
-
2011
- Identifiant
-
NCT01325740
- Auteurs
-
Seaside Therapeutics, Inc.
- Source
- ClinicalTrials.gov
- Type de référence
- clinical_trial
- Éditeur
- Seaside Therapeutics, Inc.
- Source de métadonnées
- clinicaltrials.gov
Résumé
The study will consist of a Screening period (up to 14 days), a Treatment period, and a Follow-Up period. Sixteen subjects will be enrolled into two sequential dose cohorts - 10 or 30 mg (or matching placebo) across four study centers.